Drug Profile
Insulin - MannKind Corporation
Alternative Names: Afresa®; Afrezza; Insulin human - MannKind Corporation; Insulin inhalation - MannKind Corporation; Technosphere® InsulinLatest Information Update: 23 Feb 2024
Price :
$50
*
At a glance
- Originator MannKind Corporation
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 15 Feb 2024 MannKind Corporation announces intention to submit regulatory application to the US FDA for Type 1 diabetes mellitus and Type 2 diabetes mellitus (In children, In adolescents) in 2025
- 15 Feb 2024 MannKind Corporation completes enrolment in its phase III INHALE-1 trial for Type 2 diabetes mellitus (In adolescents, In children) in USA (Inhalation) (NCT04974528)
- 15 Feb 2024 MannKind Corporation completes enrolment in its phase III INHALE-1 trial for Type 1 diabetes mellitus (In adolescents, In children) in USA (Inhalation) (NCT04974528)